Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

German study reveals Real-World use of PRRT for neuroendocrine tumors

NCT ID NCT07653126

Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 117 people with gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) who received a type of radiation therapy called PRRT in German clinics. Researchers collected information on patient characteristics, treatment timing, and how PRRT was given in everyday practice. The goal was to better understand real-world treatment patterns, not to test a new drug.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE/DOTATOC or Lutathera®
What this could lead to
If successful, this study could help doctors better understand how PRRT is used in real-world settings, potentially improving treatment guidelines for neuroendocrine tumors.
What could go wrong
This is a retrospective observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to other countries or healthcare systems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

117 people

The number who actually took part.

Started

Apr 2023

Finished

Sep 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult GEP-NET patients in Germany who received their first cycle of primary PRRT between 01 July 2020 and 30 June 2021.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Patients with a confirmed diagnosis of GEP-NET (any localization of the primary tumor including cancer of unknown primary origin \[CUP\], any Grade). * Patients with a first cycle of primary PRRT of home-brew 177Lu-DOTATATE/DOTATOC or Lutathera® between 01 July 2020 and 30 June 2021. Exclusion criteria: * Received a combination of PRRT with chemotherapy. * Received a combination of PRRT with a radionuclide other than lutetium-177 (e.g., yttrium-90).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastro-enteropancreatic neuroendocrine tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

digestive system neuroendocrine neoplasm neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastro-enteropancreatic neuroendocrine tumor

Contacts and locations

Locations

  • Novartis Investigative Site

    Essen, Germany

  • Novartis Investigative Site

    Heidelberg, Germany

  • Novartis Investigative Site

    München, Germany

  • Novartis Investigative Site

    Rostock, Germany

  • Novartis Investigative Site

    Stuttgart, Germany

  • Novartis Investigative Site

    Tübingen, Germany

  • Novartis Investigative Site

    Würzburg, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.